Sol Gel Technologies Ltd (OQ:SLGL)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 28, 2024 07:00 am ET

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...

May 20, 2024 07:00 am ET

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 16, 2024 06:00 am ET

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Apr 01, 2024 07:00 am ET

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...

Mar 13, 2024 07:00 am ET

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib...

Nov 30, 2023 07:00 am ET

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products,...

Nov 28, 2023 08:06 am ET

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Nov 09, 2023 07:00 am ET

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products,...

Aug 30, 2023 08:00 am ET

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and...

Aug 10, 2023 07:00 am ET

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 06, 2023 07:30 am ET

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. TWYNEO and EPSOLAY are two innovative, large-market, dermatology products that were developed by Sol-Gel. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that is renewable for subsequent five-year periods.

Jun 06, 2023 07:00 am ET

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

May 12, 2023 07:00 am ET

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3-ready, and an earlier-stage SGT-210, today announced financial...

Mar 20, 2023 07:00 am ET

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune & Inflammatory...

Mar 10, 2023 07:00 am ET

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced financial results for the full year ended December 31, 2022 and...

Jan 27, 2023 07:29 am ET

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced...

Jan 27, 2023 07:00 am ET

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced today the acquisition of...

Nov 10, 2022 04:00 am ET

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for...

Oct 03, 2022 08:00 am ET

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Aug 04, 2022 06:00 am ET

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jun 01, 2022 08:00 am ET

Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference

May 17, 2022 07:00 am ET

Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference

May 13, 2022 07:00 am ET

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Apr 25, 2022 07:00 am ET

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced today the Food and Drug Administration...

Apr 14, 2022 08:30 am ET

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Mar 30, 2022 07:00 am ET

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Mar 25, 2022 11:00 am ET

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Dec 22, 2021 04:05 pm ET

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company...

Dec 21, 2021 07:00 am ET

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Nov 11, 2021 07:00 am ET

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Nov 09, 2021 07:05 am ET

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate...

Nov 04, 2021 07:30 am ET

Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), (“Sol-Gel”), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced a new agreement with...

Sep 22, 2021 07:30 am ET

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sep 09, 2021 08:30 am ET

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Aug 04, 2021 07:05 am ET

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the second...

Jul 27, 2021 09:15 am ET

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Jul 20, 2021 07:05 am ET

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Jun 28, 2021 05:10 am ET

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive...

Jun 28, 2021 05:00 am ET

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.

May 27, 2021 07:00 am ET

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that...

May 13, 2021 07:05 am ET

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stagedermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results...

Apr 27, 2021 10:02 am ET

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Mar 04, 2021 07:05 am ET

Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update

Feb 24, 2021 07:05 am ET

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the...

Jan 11, 2021 07:05 am ET

Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference

Dec 07, 2020 07:05 am ET

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris

Nov 12, 2020 07:05 am ET

Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update

Nov 09, 2020 07:05 am ET

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020

Nov 04, 2020 04:05 pm ET

Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will...

Sep 10, 2020 04:01 pm ET

Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea

Sep 08, 2020 07:05 am ET

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September

Sep 03, 2020 07:05 am ET

Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®

Aug 06, 2020 07:08 am ET

Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update

Jul 29, 2020 07:05 am ET

Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020

Jul 28, 2020 07:05 am ET

Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021

Jun 29, 2020 07:00 am ET

Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates

Jun 16, 2020 04:05 pm ET

Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

May 27, 2020 09:00 am ET

Sol-Gel to Present at Upcoming Healthcare Investor Conferences

May 14, 2020 07:05 am ET

Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update

May 07, 2020 04:05 pm ET

Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020

Apr 13, 2020 07:05 am ET

Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment

Mar 25, 2020 09:25 am ET

Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

Mar 24, 2020 04:05 pm ET

Sol-Gel Technologies Reports Full Year 2019 Financial Results and Corporate Update

Mar 24, 2020 04:00 pm ET

Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences industry. At the event, management teams will present a business overview and highlights using an online, digital meeting format.

Mar 19, 2020 05:45 pm ET

Sol-Gel Technologies to Report Full Year 2019 Financial Results and Corporate Update

Feb 19, 2020 09:25 am ET

Sol-Gel to Present at the Cowen 40th Annual Health Care Conference

Feb 14, 2020 06:45 am ET

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares

Feb 13, 2020 04:05 pm ET

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), today announced positive topline data for its open-label, long-term safety study, evaluating Epsolay®, microencapsulated benzoyl peroxide cream, 5%, in papulopustular rosacea for a treatment...

Feb 05, 2020 07:05 am ET

Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases today...

Jan 21, 2020 04:05 pm ET

Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® (microencapsulated benzoyl peroxide cream, 5%) for the treatment of...

Jan 08, 2020 07:00 am ET

Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host a conference call today to discuss results from two Phase 3 clinical trials for Twyneo®, an investigational combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide...

Jan 02, 2020 07:30 am ET

Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar keratoderma type...

Dec 30, 2019 07:05 am ET

Sol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an investigational, combination of microencapsulated tretinoin 0.1% and microencapsulated benzoyl peroxide 3% cream,...

Nov 13, 2019 07:05 am ET

Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update

Oct 16, 2019 07:05 am ET

Sol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay® microencapsulated benzoyl...

Aug 13, 2019 07:05 am ET

Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update

Aug 08, 2019 08:10 am ET

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

Jul 25, 2019 06:00 am ET

Sol-Gel Technologies Hosting Analyst & Investor Day

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host an Analyst and Investor Day today in New York beginning at 8:30 a.m. ET. During the meeting, the company will review the recently announced, positive Phase III EPSOLAY® data in papulopustular...

Jul 08, 2019 07:05 am ET

Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), today announced positive results from its Phase 3 program evaluating Epsolay® microencapsulated benzoyl peroxide cream, 5%, made with the Company’s proprietary...

Jun 17, 2019 07:00 am ET

Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019

May 28, 2019 09:00 am ET

Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo

May 23, 2019 04:05 pm ET

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in June

May 22, 2019 07:05 am ET

Sol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update

Apr 18, 2019 04:05 pm ET

Sol-Gel Technologies Announces Participation in Upcoming Investor Conference

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

Apr 15, 2019 04:28 pm ET

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Apr 09, 2019 07:25 am ET

Market Trends Toward New Normal in American Homes 4 Rent, Huami, electroCore, Reeds, Clipper Realty, and Sol-Gel Technologies — Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Homes 4 Rent (NYSE:AMH), Huami Corporation (NYSE:HMI),...

Mar 21, 2019 04:05 pm ET

Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update

Feb 06, 2019 09:23 am ET

Sol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

Feb 06, 2019 07:45 am ET

Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%

DUBLIN, Feb. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Zovirax® Cream, 5% (acyclovir cream, 5%) developed in collaboration with Sol-Gel Technologies Ltd. (NASDAQ: SLGL). The Company anticipates launching the product this month.

Jan 15, 2019 07:05 am ET

Sol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization

Dec 17, 2018 07:05 am ET

Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris

Dec 04, 2018 04:05 pm ET

Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo

Nov 29, 2018 04:05 pm ET

Sol-Gel Technologies Announces Participation in Upcoming Investor Conference

Nov 21, 2018 08:10 am ET

Factors of Influence in 2018, Key Indicators and Opportunity within MongoDB, DLH, Sol-Gel Technologies, National Vision, NCS Multistage, and NI — New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MongoDB, Inc. (NASDAQ:MDB), DLH Holdings Corp. (NASDAQ:DLHC), Sol-Gel...

Nov 13, 2018 04:05 pm ET

Sol-Gel Technologies Reports Third Quarter 2018 Financial Results

Nov 05, 2018 04:05 pm ET

Sol-Gel Technologies Announces Participation in Upcoming Investor Conference

Nov 01, 2018 04:05 pm ET

Sol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo

Sep 25, 2018 04:05 pm ET

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea

Sep 13, 2018 04:05 pm ET

Sol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors

Sep 04, 2018 04:05 pm ET

Sol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris

Aug 15, 2018 04:05 pm ET

Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo

Aug 08, 2018 07:05 am ET

Sol-Gel Technologies Reports Second Quarter 2018 Financial Results

Jun 18, 2018 04:33 pm ET

Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

May 29, 2018 04:05 pm ET

Sol-Gel Technologies Announces Participation in Upcoming Investor Conferences

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

May 15, 2018 04:05 pm ET

Sol-Gel Technologies Reports First Quarter 2018 Financial Results

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today...

Mar 26, 2018 04:05 pm ET

Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website

NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended...

Mar 26, 2018 07:05 am ET

Sol-Gel Technologies Reports Fourth Quarter and Full Year 2017 Financial Results

NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin...

Feb 15, 2018 04:30 pm ET

Sol-Gel’s Phase 2 Data on TWIN and VERED to be Presented at the 2018 American Academy of Dermatology Annual Meeting

NESS ZIONA, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced...

Feb 05, 2018 04:01 pm ET

Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NESS ZIONA, Israel, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced...

Jan 31, 2018 06:46 pm ET

Sol-Gel Technologies Ltd. Announces Pricing of Initial Public Offering

NESS ZIONA, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (“Sol-Gel”) (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced...

Ad blocking detected

Sol Gel Technologies Ltd (OQ:SLGL)

Business Focus: Bio Therapeutic Drugs